HC Wainwright Comments on Aethlon Medical FY2031 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Investment analysts at HC Wainwright issued their FY2031 EPS estimates for Aethlon Medical in a report issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth expects that the medical equipment provider will earn $0.07 per share for the year. HC Wainwright has a “Neutral” rating and a $1.50 price objective on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($16.15) per share.

A number of other equities analysts have also recently commented on AEMD. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $1.50.

Aethlon Medical Price Performance

Shares of AEMD opened at $2.89 on Wednesday. The firm has a 50 day simple moving average of $4.55 and a two-hundred day simple moving average of $8.58. Aethlon Medical has a one year low of $2.63 and a one year high of $137.00. The company has a market cap of $1.88 million, a P/E ratio of -0.08 and a beta of 1.41.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing the consensus estimate of ($3.92) by ($0.10).

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.